Pharmaceutical Biochemistry, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Médecins Sans Frontières Switzerland, Geneva, Switzerland.
PLoS One. 2021 Feb 3;16(2):e0245372. doi: 10.1371/journal.pone.0245372. eCollection 2021.
Strict storage recommendations for insulin are difficult to follow in hot tropical regions and even more challenging in conflict and humanitarian emergency settings, adding an extra burden to the management of people with diabetes. According to pharmacopeia unopened insulin vials must be stored in a refrigerator (2-8°C), while storage at ambient temperature (25-30°C) is usually permitted for the 4-week usage period during treatment. In the present work we address a critical question towards improving diabetes care in resource poor settings, namely whether insulin is stable and retains biological activity in tropical temperatures during a 4-week treatment period. To answer this question, temperature fluctuations were measured in Dagahaley refugee camp (Northern Kenya) using log tag recorders. Oscillating temperatures between 25 and 37°C were observed. Insulin heat stability was assessed under these specific temperatures which were precisely reproduced in the laboratory. Different commercialized formulations of insulin were quantified weekly by high performance liquid chromatography and the results showed perfect conformity to pharmacopeia guidelines, thus confirming stability over the assessment period (four weeks). Monitoring the 3D-structure of the tested insulin by circular dichroism confirmed that insulin monomer conformation did not undergo significant modifications. The measure of insulin efficiency on insulin receptor (IR) and Akt phosphorylation in hepatic cells indicated that insulin bioactivity of the samples stored at oscillating temperature during the usage period is identical to that of the samples maintained at 2-8°C. Taken together, these results indicate that insulin can be stored at such oscillating ambient temperatures for the usual four-week period of use. This enables the barrier of cold storage during use to be removed, thereby opening up the perspective for easier management of diabetes in humanitarian contexts and resource poor settings.
在炎热的热带地区,严格遵循胰岛素的储存建议非常困难,在冲突和人道主义紧急情况下更是如此,这给糖尿病患者的管理增加了额外的负担。根据药典规定,未开封的胰岛素小瓶必须存放在冰箱中(2-8°C),而在治疗期间的 4 周使用期内,室温(25-30°C)下的储存通常是允许的。在本工作中,我们针对在资源匮乏环境中改善糖尿病护理提出了一个关键问题,即在 4 周治疗期间,胰岛素在热带温度下是否稳定并保持生物活性。为了回答这个问题,我们使用日志标签记录器测量了达加哈利难民营(肯尼亚北部)的温度波动。观察到温度在 25 到 37°C 之间波动。在这些特定温度下评估了胰岛素的热稳定性,这些温度在实验室中得到了精确再现。通过高效液相色谱法每周定量分析了不同商业化的胰岛素制剂,结果与药典指南完全一致,因此在评估期(四周)内证实了稳定性。通过圆二色性监测测试胰岛素的 3D 结构,证实胰岛素单体构象没有发生显著变化。在肝细胞中检测胰岛素对胰岛素受体(IR)和 Akt 磷酸化的效率表明,在使用期间储存在振荡温度下的样品的胰岛素生物活性与保存在 2-8°C 下的样品相同。综上所述,这些结果表明,胰岛素可以在这种波动的环境温度下储存通常的 4 周使用期。这消除了使用过程中冷藏的障碍,从而为在人道主义环境和资源匮乏的环境中更轻松地管理糖尿病开辟了前景。